The activation of GPR65 on tumor-associated macrophages (TAMs) is a key tumor-promoting process and GPR65 has been previously described as a genetically validated target in cancer. It was demonstrated that GPR65 functions as an immune checkpoint in acidic tumor microenvironment (TME), as it is activated by low pH in the TME.